-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Buchang Pharmaceutical announced that it plans to invest 50 million yuan to invest in Suzhou Yuanhepu Huazhixin Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Intelligent Fund.
Aiqicha search shows that Zhixin Fund was established on November 23, 2020 with a registered capital of 38 billion yu.
Its business scope includes general projects: private equity funds are engaged in equity investment, investment management, asset management and other activiti.
Judging from the proportion of investment by the main partners of the fund, Suzhou Yuanhe Holdings .
, L.
, which is backed by Yu Renrong, the founder of Weir, accounted for 211%; Shanghai Qingen Asset Management Partnership (Limited Partnership) accounted for 186%; Suzhou Innovation Industrial Development Guidance Fund (Limited Partnership) accounted for 64%; Yangtze River Delta Synergy Advantage Industry Equity Investment Partnership (Limited Partnership) accounted for 04%; Nanjing Pukou Zhihui Emerging Industry Investment Fund Partnership (Limited Partnership) accounted for 4
It is reported that the fundraising amount of the Zhixin Fund this time is 148 billion yu.
After the fundraising is completed, the overall size of the fund will reach 258 billion yuan, which is mainly invested in the semiconductor industry cha.
This also means that Buchang Pharmaceutical will enter the semiconductor indust.
Semiconductors refer to materials with electrical conductivity between conductors and insulators at room temperatu.
They are the basis for the development of electronic information and play a crucial role in the development of science, technology and econo.
The semiconductor industry has grown strongly against the trend in recent years, but the sector's overall profit slowed down in the first quarter of this ye.
Some industry analysts pointed out that considering factors such as downstream market adjustment, the market is worried that the semiconductor industry, which has grown rapidly in recent years, will face an inflection point of adjustment, and it is even expected that it will enter a recession in 202 For cross-border, Buchang Pharmaceutical stated in the announcement that the participation in the investment in Zhixin Fund is to further promote the company's development strate.
It is found that in addition to cross-border semiconductors, since its listing in November 2016, Buchang Pharmaceutical has also announced to invest in two equity investment funds, namely Suzhou Shengtao Medical Investment Partnership (Limited Partnership) and Wuhan Ruifu Medical and Health Equity Investment partnership (limited partnership), the investment direction of these two funds are both medical and health related fiel.
Some analysts say that listed companies invest in setting up equity investment funds, which is beneficial to the company's market value manageme.
At the same time, after the establishment of the fund, listed companies invest in equity around their own industrial chain, which can better capture the technology in the industry, and then initiate mergers and acquisitio.
According to public information, Buchang Pharmaceutical is an enterprise engaged in the research, development, production and sales of Chinese patent medicin.
In addition, Buchang Pharmaceutical is also stepping into the high-tech fields of medicine such as biopharmaceuticals and vaccines, and constantly enriching the product matr.
As of December 2021, the company has 227 products under development, including 12 traditional Chinese medicines, 193 chemical medicines, 17 biological medicines, and 5 medical devic.
Judging from the company's performance in the past year, Buchang Pharmaceutical's 2021 third quarter report, 2021 annual report, and 2022 first quarter report, the revenue was 1377 billion, 1763 billion, and 200 billion, respective.
Judging from the company's profit performance, the net profit was 274 billion, 289 billion and 430 million respectively, with year-on-year growth rates of -73%, -372% and 91% respective.
As a pharmaceutical company, Buchang Pharmaceutical, this cross-border semiconductor can be said to be a relatively bold attem.
It may take time to prove whether the company can create new growth points in the futu.
Aiqicha search shows that Zhixin Fund was established on November 23, 2020 with a registered capital of 38 billion yu.
Its business scope includes general projects: private equity funds are engaged in equity investment, investment management, asset management and other activiti.
Judging from the proportion of investment by the main partners of the fund, Suzhou Yuanhe Holdings .
, L.
, which is backed by Yu Renrong, the founder of Weir, accounted for 211%; Shanghai Qingen Asset Management Partnership (Limited Partnership) accounted for 186%; Suzhou Innovation Industrial Development Guidance Fund (Limited Partnership) accounted for 64%; Yangtze River Delta Synergy Advantage Industry Equity Investment Partnership (Limited Partnership) accounted for 04%; Nanjing Pukou Zhihui Emerging Industry Investment Fund Partnership (Limited Partnership) accounted for 4
It is reported that the fundraising amount of the Zhixin Fund this time is 148 billion yu.
After the fundraising is completed, the overall size of the fund will reach 258 billion yuan, which is mainly invested in the semiconductor industry cha.
This also means that Buchang Pharmaceutical will enter the semiconductor indust.
Semiconductors refer to materials with electrical conductivity between conductors and insulators at room temperatu.
They are the basis for the development of electronic information and play a crucial role in the development of science, technology and econo.
The semiconductor industry has grown strongly against the trend in recent years, but the sector's overall profit slowed down in the first quarter of this ye.
Some industry analysts pointed out that considering factors such as downstream market adjustment, the market is worried that the semiconductor industry, which has grown rapidly in recent years, will face an inflection point of adjustment, and it is even expected that it will enter a recession in 202 For cross-border, Buchang Pharmaceutical stated in the announcement that the participation in the investment in Zhixin Fund is to further promote the company's development strate.
It is found that in addition to cross-border semiconductors, since its listing in November 2016, Buchang Pharmaceutical has also announced to invest in two equity investment funds, namely Suzhou Shengtao Medical Investment Partnership (Limited Partnership) and Wuhan Ruifu Medical and Health Equity Investment partnership (limited partnership), the investment direction of these two funds are both medical and health related fiel.
Some analysts say that listed companies invest in setting up equity investment funds, which is beneficial to the company's market value manageme.
At the same time, after the establishment of the fund, listed companies invest in equity around their own industrial chain, which can better capture the technology in the industry, and then initiate mergers and acquisitio.
According to public information, Buchang Pharmaceutical is an enterprise engaged in the research, development, production and sales of Chinese patent medicin.
In addition, Buchang Pharmaceutical is also stepping into the high-tech fields of medicine such as biopharmaceuticals and vaccines, and constantly enriching the product matr.
As of December 2021, the company has 227 products under development, including 12 traditional Chinese medicines, 193 chemical medicines, 17 biological medicines, and 5 medical devic.
Judging from the company's performance in the past year, Buchang Pharmaceutical's 2021 third quarter report, 2021 annual report, and 2022 first quarter report, the revenue was 1377 billion, 1763 billion, and 200 billion, respective.
Judging from the company's profit performance, the net profit was 274 billion, 289 billion and 430 million respectively, with year-on-year growth rates of -73%, -372% and 91% respective.
As a pharmaceutical company, Buchang Pharmaceutical, this cross-border semiconductor can be said to be a relatively bold attem.
It may take time to prove whether the company can create new growth points in the futu.
